64 related articles for article (PubMed ID: 9316450)
1. Dopamine requires ascorbic acid to be the prolactin release-inhibiting factor.
Shin SH; Si F; Chang A; Ross GM
Am J Physiol; 1997 Sep; 273(3 Pt 1):E593-8. PubMed ID: 9316450
[TBL] [Abstract][Full Text] [Related]
2. Reexamination of dopamine as the prolactin-release inhibiting factor (PIF): supplementary agent may be required for dopamine to function as the physiological PIF.
Shin SH; Hanna SF; Hong M; Jhamandas K
Can J Physiol Pharmacol; 1990 Sep; 68(9):1226-30. PubMed ID: 1980429
[TBL] [Abstract][Full Text] [Related]
3. Ascorbic acid potentiates the inhibitory effect of dopamine on prolactin release: a putative supplementary agent for PIF.
Shin SH; Stirling RG; Hanna S; Lim M; Wilson JX
Endocrinol Exp; 1990 Mar; 24(1-2):151-8. PubMed ID: 1972918
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 receptor mediates both inhibitory and stimulatory actions on prolactin release.
Chang A; Shin SH; Pang SC
Endocrine; 1997 Oct; 7(2):177-82. PubMed ID: 9549043
[TBL] [Abstract][Full Text] [Related]
5. Differential inhibition of dopamine and bromocriptine on induced prolactin release: multiple sites for the inhibition of dopamine.
Hanna S; Shin SH
Neuroendocrinology; 1992 May; 55(5):591-9. PubMed ID: 1316563
[TBL] [Abstract][Full Text] [Related]
6. High concentrations of dopamine and epinephrine protect dopaminergic D2 receptors from inactivation by phenoxybenzamine on primary cultured rat lactotrophs.
Shin SH; Heisler RL
Neuroendocrinology; 1992 Sep; 56(3):407-14. PubMed ID: 1436379
[TBL] [Abstract][Full Text] [Related]
7. Phenoxybenzamine selectively and irreversibly inactivates dopaminergic D2 receptors on primary cultured rat lactotrophs.
Shin SH; McAssey K; Heisler RL; Szabo MS
Neuroendocrinology; 1992 Sep; 56(3):397-406. PubMed ID: 1436378
[TBL] [Abstract][Full Text] [Related]
8. Long term exposure to dopamine reverses the inhibitory effect of endothelin-1 on prolactin secretion.
Kanyicska B; Livingstone JD; Freeman ME
Endocrinology; 1995 Mar; 136(3):990-4. PubMed ID: 7867609
[TBL] [Abstract][Full Text] [Related]
9. Activation of the adrenergic beta-receptor stimulates prolactin release from primary cultured pituitary cells.
Shin SH; Barton RE
Neuroendocrinology; 1993 Apr; 57(4):670-7. PubMed ID: 8396220
[TBL] [Abstract][Full Text] [Related]
10. Ascorbic acid potentiates the inhibitory effect of dopamine on prolactin release in primary cultured rat pituitary cells.
Shin SH; Stirling R
J Endocrinol; 1988 Aug; 118(2):287-94. PubMed ID: 3171470
[TBL] [Abstract][Full Text] [Related]
11. Pertussis toxin uncouples dopamine agonist inhibition of prolactin release.
Cronin MJ; Myers GA; MacLeod RM; Hewlett EL
Am J Physiol; 1983 May; 244(5):E499-504. PubMed ID: 6682634
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of the adenosine 3',5'-monophosphate and the Ca2+ messenger systems together reverse dopaminergic inhibition of prolactin release.
Delbeke D; Dannies PS
Endocrinology; 1985 Aug; 117(2):439-46. PubMed ID: 2990850
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of prolactin secretion after short term or pulsatile exposure to dopamine in superfused anterior pituitary cell aggregates.
Denef C; Baes M; Schramme C
Endocrinology; 1984 Apr; 114(4):1371-8. PubMed ID: 6705740
[TBL] [Abstract][Full Text] [Related]
14. Relationships between dopamine-induced changes in cytosolic free calcium concentration ([Ca2+]i) and rate of prolactin secretion. Elevated [Ca2+]i does not indicate prolactin release.
Chang A; Shin SH
Endocrine; 1997 Dec; 7(3):343-9. PubMed ID: 9657072
[TBL] [Abstract][Full Text] [Related]
15. Single lactotroph responses to dopamine, angiotensin II, and culture duration.
Anderson JM; Cronin MJ
Am J Physiol; 1990 Jan; 258(1 Pt 1):E24-31. PubMed ID: 2301569
[TBL] [Abstract][Full Text] [Related]
16. The effect of dopamine on thyrotropin-releasing hormone-induced prolactin secretion in vitro.
Fagin KD; Neill JD
Endocrinology; 1981 Dec; 109(6):1835-40. PubMed ID: 6796383
[TBL] [Abstract][Full Text] [Related]
17. Episodic prolactin release after removal of dopamine inhibition in vitro.
Swearingen KC; MartÃnez de la Escalera G; Weiner RI
Bol Estud Med Biol; 1990; 38(3-4):43-8. PubMed ID: 2103743
[TBL] [Abstract][Full Text] [Related]
18. The 7315a pituitary tumor is refractory to dopaminergic inhibition of prolactin release but contains dopamine receptors.
Cronin MJ; Valdenegro CA; Perkins SN; MacLeod RM
Endocrinology; 1981 Dec; 109(6):2160-6. PubMed ID: 7308146
[No Abstract] [Full Text] [Related]
19. Adenosine 3',5'-monophosphate (cAMP) and calcium-calmodulin interrelation in the control of prolactin secretion: evidence for dopamine inhibition of cAMP accumulation and prolactin release after calcium mobilization.
Schettini G; Cronin MJ; MacLeod RM
Endocrinology; 1983 May; 112(5):1801-7. PubMed ID: 6299710
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptide Y suppresses prolactin secretion from rat anterior pituitary cells: evidence for interactions with dopamine through inhibitory coupling to calcium entry.
Wang J; Ciofi P; Crowley WR
Endocrinology; 1996 Feb; 137(2):587-94. PubMed ID: 8593806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
